1 **ANALYSIS OF IMMUNE ESCAPE VARIANTS FROM ANTIBODY-BASED THERAPEUTICS AGAINST**
2 **COVID-19.**

3
4 Daniele Focosi^{1,#}

5 Fabrizio Maggi^{2,3}

6 Massimo Franchini⁴

7 Scott McConnell⁵

8 Arturo Casadevall⁵

9
10 ¹North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy.

11 ²Department of Medicine and Surgery, University of Insubria, Varese, Italy.

12 fabrizio.maggi63@gmail.com

13 ³Laboratory of Microbiology, ASST Sette Laghi, Varese, Italy.

14 ⁴Division of Transfusion Medicine, Carlo Poma Hospital, 46100 Mantua, Italy;

15 massimo.franchini@asst-mantova.it

16 ⁵Department of Medicine, Johns Hopkins School of Public Health and School of Medicine, Baltimore,

17 MD, USA; acasade1@jhu.edu; smcconn8@jhu.edu

18
19 [#]corresponding author: via Paradisa 2, 56124 Pisa, Italy. E-mail: daniele.focosi@gmail.com

20
21 **Word count:** abstract 108; body 4370.

22 **Keywords:** SARS-CoV-2; COVID-19; Spike; convalescent plasma; viral clearance.; Q493R; E484K;
23 deletions

24 **Abbreviations:** nAb : neutralizing antibodies; CCP : COVID19 convalescent plasma; PSM : propensity
25 score-matched; RCT : randomized controlled trials.

26 **Author contributions:** D.F. conceived the manuscript; F.M. analyzed the literature; S.M. provided the
27 figure and revised the final version; A.C. and M.F. revised the final version. All authors approved the
28 final version.

29

30 **Abstract**

31 Accelerated SARS-CoV-2 evolution under selective pressure by massive deployment of neutralizing
 32 antibody-based therapeutics is a concern with potentially severe implications for public health. We
 33 review here reports of documented immune escape after treatment with monoclonal antibodies
 34 and COVID19 convalescent plasma (CCP). While the former is mainly associated with specific single
 35 amino acid mutations at residues within the receptor-binding domain (e.g., E484K/Q, Q493R, and
 36 S494P), the few cases of immune evasion after CCP were associated with recurrent deletions within
 37 the N-terminal domain of Spike protein (e.g, ΔHV69-70, ΔLGVY141-144 and ΔAL243-244).
 38 Continuous genomic monitoring of non-responders is needed to better understand immune escape
 39 frequencies and fitness of emerging variants.

40

41

42

43 Introduction

44 SARS-CoV-2 Spike protein is the target of neutralizing antibody (nAb)-based therapeutics. Control of
45 the COVID19 pandemic is being hampered by continued evolution of SARS-CoV-2, which includes
46 mutations in the Spike protein that can affect immunogenicity and antibody-mediated
47 neutralization. Evolutionary modeling suggests that SARS-CoV-2 strains harboring 1-2 deleterious
48 mutations naturally exist, and their frequency increases steeply under positive selection by
49 monoclonal antibodies (mAb) and vaccines [1]. In 2% of COVID cases, SARS-CoV-2 variants with
50 multiple mutations occur, including in the Spike glycoprotein, which can become the dominant
51 strains in as little as one month of persistent in-patient virus replication [2]. While mutations can
52 occur as a natural phenomenon of SARS-CoV-2 RNA replication and editing, the pace of mutagen
53 emergence can also be affected by small-chemical antivirals (e.g. remdesivir [3] or molnupiravir [4]).
54 Since antibody-based therapies targeting the spike protein would also put selective pressure on
55 SARS-CoV-2, it is reasonable to assume that widespread deployment of nAb-based therapeutics
56 could accelerate Spike immune escape by selecting for variants resist neutralization.

57 Mutations that confer *in vitro* resistance to therapeutic anti-Spike mAbs have been characterized
58 with various methods, and are informative about treatment-emergent immune escape. Deep
59 mutational scanning (DMS) predicts protein expression, ACE2 binding, and mAb binding [5]. The
60 method was first deployed with yeast display libraries [6], then evolved to phage display libraries
61 (https://jbloomlab.github.io/SARS-CoV-2-RBD_MAP_clinical_Abs/) [44] and finally mammalian cell
62 surface display [7]. nAb binding is common within the fusion peptide and in the linker region before
63 heptad repeat (HR) region 2. The complete escape maps forecast SARS-CoV-2 mutants emerging
64 during treatment with mAbs, and allow the design of escape-resistant nAb cocktails. Complete map
65 of SARS-CoV-2 RBD mutations that escape bamlanivimab and its cocktail with etesevimab have been
66 generated [8, 9].

67 Although DMS was also applied to polyclonal antibodies in COVID19 convalescent plasma (CCP) [10],
68 the problem is much more complex such that it is almost impossible to identify escape mutations in
69 CCP or vaccinee elicited sera, given the huge heterogeneity in antibody response among CCP donors
70 and vaccinees, respectively. *In vitro*, continuous passaging of SARS-CoV-2 in the presence of a CCP
71 unit with nAb titer $>1:10^4$ led to Δ F140 Spike mutation at day 45, followed by E484K at day 73, and
72 an insertion in the N-terminal domain (NTD): these accumulating mutations led to complete immune
73 escape [11]. Similarly, K417N, E484K, and N501Y mutations were selected when pseudotyped SARS-
74 CoV-2 was cultured in the presence of vaccine-elicited mAbs [12]. Although some have speculated
75 that the large-scale use of CCP for COVID-19 could have played a role in the emergence of variants
76 there is no evidence for such an effect and the most likely explanation for regular emergence of
77 variants has been huge number of affected individuals since each infection case provides a natural
78 opportunity for variant creation [13].

79 *In vivo*, while intra-host SARS-CoV-2 mutation development is typically very low [14], faster mutation
80 rates (referred as “accelerated evolution”) have been found in longitudinal studies of
81 immunodeficient patients who had persistent SARS-CoV-2 infections for several months and were
82 treated with nAb-based therapeutics. In this study we analyze and compare the available mutational
83 data from SARS-CoV-2 under *in vitro* and *in vivo* selection and demonstrate that mAb and polyclonal
84 (CCP) therapies elicit different types of mutational patterns.

85

86 Methods

We mined PubMed (which also indexes the bioRxiv and medRxiv preprint servers) for keywords related to COVID19 (“COVID19”, “SARS-CoV-2”), immune escape (“immune escape”, “treatment-emergent resistance”) and nAb-based therapeutics (“convalescent plasma”, “casirivimab”, “imdevimab”, “bamlanivimab”, etesevimab”, “sotrovimab, “regdanvimab”) both *in vitro* and *in vivo*. Clinical cases were annotated for eventual underlying immune deficiency, concurrent treatments and outcome. Figure 1 reports the study selection process according to PRISMA 2020 guidelines [15].

The 3D structural coordinates of the full Spike protein (PDBID 6VXX; residues 27-1252) [16] and the receptor binding domain (PDBID 7BWJ; residues 319-529) [17], solved by cryo-electron microscopy and X-ray crystallography, respectively, were used to map mutational positions of interest. Mapping on the full Spike was used to illustrate the diverse set of mutations throughout the Spike glycoprotein, while the mutations localized to the RBD were illustrated using the more complete structural model obtained through crystallography. The mutations identified in each condition of *in vivo* or *in vitro* selection were tabulated and highlighted on the structures using color coding with PyMOL [18].

Results

Our literature search revealed 32 papers that were then manually inspected to determine whether they included relevant information that was then retrieved, evaluated and organized into Tables.

Table 1 summarizes Spike protein mutations associated with *in vitro* resistance to mAbs targeting this protein. These mutations were used to filter clinical case reports of treatment resistance for evidence of immune escape (Table 2).

Table 3 summarizes Spike mutations found in clinical cases after CCP treatment, where, immune escape can be hypothesized to have occurred based on treatment failure, with the caveat that there is no definitive proof of immune escape due to heterogeneity of the (uncharacterized) polyclonal response.

Table 4 summarizes data from reports within-host clonal evolution within immunosuppressed patients not treated with nAb-based therapeutics.

Figure 2 depicts the Spike RBD mutations of concern for mAb binding detected *in vitro* and *in vivo* and the Spike mutations detected after CCP usage.

116 **Table 1.** Spike mutations associated with clinically-approved mAb resistance *in vitro*. Mutations conferring resistance to both mAbs within the cocktail are
117 underlined.

manufacturer	cocktail brand name	active ingredient (brand name)	Spike mutations associated with <i>in vitro</i> resistance	ref
Eli Lilly (AbCellera/Junshi)	n.a.	etesevimab (LyCoV016, CB6, JS016, LY3832479)	K417N/T, N460I, I472D, E484K, G485P, <u>Q493R/K</u>	[8, 9, 19]
		bamlanivimab (LY-CoV555, LY3819253)	L452R, E484K, G485P, <u>Q493R/K</u> , S494P	
Regeneron/Roche	REGN-COV2 (Ronapreve®)	imdevimab (REGN10987)	<u>E406W</u> , K444x, G446x	[8]
		casirivimab (REGN10933)	<u>E406W</u> , F486x	
Celltrion	-	regdanvimab (CT-P59)	n.a.	n.a.

118

119 **Table 2.** Case reports of immune escape after anti-Spike mAb treatment.

mAb type	age/sex (identifier)	condition (treatments)	day mAb administered	other antiviral treatments	SARS- CoV-2 strain	Spike mutations	first detected at day	outcome	ref
REGN-CoV2 cocktail	45/M	antiphospholipid syndrome (steroids, rituximab, ruxolitinib, IVIg, cyclophosphamide)	45	remdesivir (5+10+5 days)	n.a.	E484K/A, Y489H, Q493K and N501Y	75	death	Choi <i>et al</i> [20] Clarke <i>et al</i> [21]
bamlanivimab monotherapy (700 mg iv)	n.a./n.a. (B2_11)	immunocompetent	median 4.5	n.a.	n.a.	E484K	3 after mAb	n.a.	Choudhary <i>et al</i> [22]
	n.a./n.a. (B2_10)			n.a.	n.a.	S494P	6 after mAb	n.a.	
	n.a./n.a. (B2_8)			n.a.	n.a.	E484K	4 after mAb	n.a.	
	n.a./n.a. (B2_7)			n.a.	n.a.	E484K	6 after mAb	n.a.	
	n.a./n.a. (B2_6)			n.a.	n.a.	S494P +E484K (frequency <20%)	3 after mAb	n.a.	
	n.a./n.a.			n.a.	n.a.	E484Q	4 after mAb	n.a.	

	(B2_5)								
	n.a./n.a. (B2_4)			n.a.	n.a.	E484K	8 after mAb	n.a.	
	n.a./n.a. (B2_3)			n.a.	n.a.	S494P	6 after mAb	n.a.	
	n.a./n.a. (B2_2)			n.a.	n.a.	E484Q	3 after mAb	n.a.	
	72/M	chronic lymphocytic leukemia and hypogammaglobulinemia (venetoclax and rituximab 17 days earlier); steroids 21-26	4 (700 mg)	1 BNT162b2 dose 20 days before CPP day 10	Alpha	E484K and Q493R	6	recovered at day 61	Truffot <i>et al</i> [23]
	55/F	acute myeloid leukemia	14	Remdesivir days 23-27	Alpha	E484K and Q493R, S494P	21	negative at day 51	Lohr <i>et al</i> [24]
	70/M	ANCA-associated vasculitis with end-stage renal disease (rituximab and prednisolone)	2	3 units of CCP at day 16	B.1	E484K →E484Q, reverted to E484K after CCP	12	died of MOF on day 20	Jensen <i>et al</i> [25]
	40/F	AIDS	3	remdesivir and 2 units of CCP	B..1.	E484K	10	recovered	
	60/M	relapsed follicular lymphoma (obinutuzumab, thiotepa, cytarabine, etoposide)	76	2 CCP units on day 57 and 1 CCP unit on day 59	B.1.17 7	E484K	87	recovered, negative at day 103	

	65/M	heart transplant recipient (about 30 years ago) (cyclosporine, azathioprine, prednisolone)	2	none	B.1.17 7	E484K	19	discharged at day 40 after 2 negative NPS	
	65/M	chronic lymphatic leukemia	45	remdesivir and 3 units of CCP days 52-62, imdevimab/casirivimab about day 70	B.1.25 8	E484K	52	recovered, negative at day 91	
	33/M	Hodgkin lymphoma (untreated)	20	dexamethasone	B.1.36 2	ΔF140 → ΔPFLGVY139-144, G485R, W258C	45	hospitalized for HL chemotherapy at end of follow-up	Bronstein <i>et al</i> [26]
	68/M	chronic lymphocytic leukemia (FCR in 2017, prednisone for AIHA, venetoclax + rituximab in 2019)	10	CPP days 12 and 26, IVIg day 21, remdesivir days 37-41	Alpha	E484Q	22	discharged day 43	
	n.a.	immunocompetent	2	n.a.	B.1.31 1	E484K	n.a.	resolved at home	Sabin <i>et al</i> [27]
	87/M	immunocompetent	2	none	Alpha	E484K +S494P	6	discharged negative at day 27	Peiffer-Smadja <i>et al</i> [28]
	35/M	Immunocompetent	2	none	Alpha	E484A/K	6	discharged, negative at day 38	
	61/M	immunocompetent	2	steroids	Alpha	E484K	12	negative at day 8, hospitalized for unrelated reasons	
	97/M	immunocompetent	4	none	Alpha	E484K	14	died at day 35 because	

								of soft tissue infection	
	64/M	heart transplant recipient	2	corticosteroids for 10 days	Alpha	Q493R	26	discharged, negative at day 48	
bamlanivimab 700 mg + etesevimab 1400 mg cocktail	n.a.	n.a.	2	n.a.	n.a.	S494P	11	recovered, not detected in samples at day	Gottlieb <i>et al</i> [29]
	73/M	cholangiocarcinoma (steroids)	2	none	Alpha	Q493R	7	died day 18	Focosi <i>et al</i> [30]
	63/M	allogeneic HSCT recipient for mycosis fungoides	n.a.	none	Alpha	Q493R	15	discharged at day 2	Guigon <i>et al</i> [31]
	n.a.	solid organ transplantation	n.a.	none	Alpha	Q493R	7	n.a.	Vellas <i>et al</i> [32]
	n.a.	solid organ transplantation	n.a.	none	Alpha	Q493R	7	n.a.	
	n.a.	solid organ transplantation	n.a.	none	Alpha	Q493R	14	n.a.	
	n.a.	solid organ transplantation	n.a.	none	Alpha	Q493K	7	n.a.	
	n.a.	solid organ transplantation	n.a.	none	Alpha	E484K	21	n.a.	
	34/F	B-ALL	<5 days	2 CCP units days 29-30	Alpha	Q493R	n.a.	all were rescued with CCP	Pommeret <i>et al</i> [33]
	62/F	Hodgkin lymphoma		1 CCP unit day 26	Alpha	Q493R	n.a.		
	63/F	follicular lymphoma		2 CCP units days 30-31	Alpha	Q493R	n.a.		
	67/F	follicular lymphoma		2 CCP units days 15-16	Alpha	n.a.	n.a.		
	57/M	chronic lymphocytic leukemia		2 CCP units days 30-31	Alpha	E484D	n.a.		

121 **Table 3.** Case reports of immune escape after CCP treatment.

age/sex (identifier)	condition	CCP schedule (and titer)	co-treatments	SARS- CoV-2 strain	Spike mutations	first detected at day	outcome	ref
71/F	chronic lymphocytic leukemia and iatrogenic hypogammaglobulinemia	70 (1:60) and 81 (1:160)	IVIg q4-6w	n.a.	ΔPFLGVYY139-145	49	negative NPS since day 105	Avanzato <i>et al</i> [34]
					ΔLG VY141-144	70 (poor causality)		
73/M	CAR-T-cell recipient	low titre days 2 and 58	remdesivir days 5- 10,63-74 dexamethasone days	GH	R190K and G1124D	13	died day 74	Hensley <i>et al</i> [35]
					ΔY144, D215G, and N501T	67		
					ΔH146	72		
70/M	B-cell depletion and hypogammaglobulinemia	63, 65, 102	remdesivir day 38- 48, 52-62 and 91- 101	n.a.	D796H and ΔHV69-70	57	died on day 102	Kemp <i>et al</i> [36]
21/M	B-acute lymphoblastic leukemia (CART tisagenlecleucel)	78, 103, 110, 123, 130, 137, 144, 158, 165, 172	remdesivir (2 5-days courses)	n.a.	3 major allele variants emerged between days 0 and 40 with an additional 4 major and 7 minor allele variants by day 144 (ΔLGV141- 143, ΔY145, ΔLG VY141-144, ΔNL211-212, N440K, V483A, and E484Q)	144	positive NPS at end of follow- up (day 250)	Truong <i>et al</i> [37]
50/M	kidney transplant recipient (tacrolimus, steroids)	1	tocilizumab day 2	B.1.369	Q493R, ΔAL243-244 had ~70% frequency; ΔLG VY141-144, E484K and Q493K had ~30%, ~20% and ~10%	21	died on day 94	Chen <i>et al</i> [38]

					frequency			
75/M	B-CLL (FCR, ibrutinib)	2 units on day 70, 2 units on days 127-128	remdesivir days 24-33 and 60-64	n.a.	H49Y, ΔY144, ΔLLA241-243, ΔAL243-244, L242H, A243P, F490S, N1178N, and C1250F	80	still positive at end of follow-up (day 333)	Monrad <i>et al</i> [39]
60/M	mantle-cell lymphoma and associated B-cell immunodeficiency (rituximab, bispecific mAb, cyclophosphamide, doxorubicin, prednisone)	31, 122	remdesivir day 30 and 122	n.a.	mutations in ORF1a but not in Spike	n.a.	still positive at end of follow-up (day 156)	Baang <i>et al</i> [40]
40/F	diffuse large B-cell lymphoma (CART) and hypogammaglobulinemia	high-titer day 2, 313	IVIg, remdesivir day 2 and 313	B.1.332	ΔLHR244-246 and A243G	313 (poor causation)	discharged day 324, cleared at day 335	Nussenblatt <i>et al</i> [41]
70/F (A)	follicular lymphoma (obinutuzumab-CHOP)	23, 34, 49, 55, 56, 62, 65, 70, 73, 77, 84, 86, 90, 94, 106	steroids	B.1.1.29	L18F, R682Q, ΔY144	50	died 5 months later	Khatamzas <i>et al</i> [42]
70/M	mantle cell lymphoma (R-BAC)	88	darunavir/ritonavir, hydroxychloroquine, methylprednisolone, tocilizumab days 1-78, remdesivir days 45-50 and 78-87, 180-184 and 210-	B.1.1	H69Y/P, V70G and S982A	238	died on day 271, still positive at day 268	Sepulcri <i>et al</i> [43]

			214, IVIg					
40/M	autologous hematopoietic stem cell transplant due to a DLBCL	2 doses on days ?	IVIg	B.1.128	Δ LGV141-143 → Δ LGVY141-144	134	negative PCR on day 196	Mendes-Correa <i>et al</i> [44]

122

123 **Table 4.** Intrahost variation in Spike sequence detected in immunocompromised patients not receiving nAb-based treatments.

age/sex (identifier)	condition	antiviral treatments	SARS- CoV-2 strain	Spike mutations	first detected at day	outcome	ref
47/F	diffuse large B cell lymphoma (rituximab plus polychemotherapy)	n.a.	B.1.1.163	Y453F, ΔHV69-70, S50L, ΔLG VY141-144, T470N, and D737G	120	negative PCR on day 132	Bazykin <i>et al</i> [45]
61/F	diffuse large B cell lymphoma stage IVB	remdesivir for 10 days, high-dose steroids for 7 days	B.1.1.401	V3G, S50L, N87S, A222V, ΔLTTRTQLPPAYTN18- 30 and ΔLG VY141-144	164	negative PCR at day 197	Borges <i>et al</i> [46]
3/F (1)	B-cell acute lymphoblastic leukemia (chemotherapy)	n.a.	20C	silent I410I (22792:C/A)	27	negative PCR at day 91	Truong <i>et al</i> [37]
2/M (3)	B-cell acute lymphoblastic leukemia	remdesivir for 5 days	20C	V483A and E484Q V70P, ΔLG V141-143, N440K	139 162	negative PCR at day 196	
37/F	advanced HIV and antiretroviral treatment failure	dexamethasone	B.1.1.273	E484K	6	negative at day 233	Karim <i>et al</i> [47]
				K417T and F490S	71		
				L455F and F456L	106		
				D427Y and N501Y	190		
80/M	chronic lymphocytic leukemia and hypogammaglobulinemic	remdesivir days 213-230, REGN- COV-2 day 265	B.52	L179	58	negative PCR day 311	Kavanagh Williamson <i>et al</i> [48]
				S255F, S477N, H655Y, D1620A, ΔHV69-70	155		
40/M	autologous hematopoietic stem cell transplant due to a DLBCL	IVIg	B.1.128	ΔLG V141-143 → ΔLG VY141-144		negative PCR on day 196	Mendes- Correa <i>et al</i> [44]
n.a./n.a.	transplant recipient	remdesivir	n.a.	S13I, T95I, E484G, F490L, ΔLG VY141-144, ΔLHRS244-247, and ΔSPRRARSV680-687	n.a.	n.a.	Weigang <i>et al</i> [49]

n.a./n.a.	18 B-cell non-Hodgkin lymphoma	44% CCP 37% remdesivir	n.a.	n.a.	requested	n.a.	Lee <i>et al</i> [50]
-----------	--------------------------------	---------------------------	------	------	-----------	------	--------------------------

124

Figure legends.

Figure 1. PRISMA flow diagram of study selection.

Figure 2.

Top panel) The full SARS-CoV-2 S (spike) glycoprotein homotrimer (PDBID 6VXX) [16] in the prefusion conformation is shown in surface representation, with each spike monomer colored a different shade of green. N-linked glycosylations which were resolved in the cryo-EM map in this structure (16/22 sequons per protomer) are displayed as magenta sticks. The receptor binding domains (RBDs), in the closed state, are highlighted in 3 shades of blue corresponding to the shade of the corresponding trimer. Escape mutations from case reports of patients treated with CCP are highlighted in orange. Spike mutations associated with immune escape from clinically approved mAb treatments in vitro or from case reports are highlighted in red, while escape mutations identified in both patients who received with clinically approved mAb treatments and CCP treatment are colored yellow. The full spike is shown oriented along the long axis (left) and rotated 90 degrees to display mutations concentrated in the RBDs. Note that mutations located on unresolved loops on the cryo-EM map of the full spike are not visualized (L18, V70, Y144, Y145, D146, R246, W258, G446, N460, I472, V483, E484, G485, F486, R682, N1178 and C1250).

Bottom panel) A table summarizing escape mutations localized to the RBD resulting from mAb treatments in vitro and case reports, as well as from CCP treatment. The crystal structure of single RBD domain (PDBID: 7BWJ)[17] from a more complete model (no missing loops) is displayed in surface view with the secondary structure superimposed in cartoon representation. Each escape mutation residue is highlighted by coloration according to the legend to right, and sidechains shown as sticks. In cases where a certain position corresponds to escape mutations from multiple treatments, the position is colored white and the label includes asterisks with the colors corresponding to each treatment where the escape mutation was identified. All figures were generated in PyMOL [18].

Discussion

Escape from nAb based therapeutics provides a crucial demonstration that these immune therapies target protective antigens, which the pathogen actively evades. Hence, the emergence of neutralizing-resistant variants in individuals receiving mAb and CCP provides powerful evidence for their antiviral activity. This evidence is independent of reduction in viral load, which has been reported with mAbs given early in disease but have been an inconsistent finding in randomized controlled trials (RCT) of CCP for COVID-19 [51].

Getting frequencies for this phenomenon from case series is not possible due to the high risk of selection biases, which would yield unrealistically high frequencies. In contrast, RCTs with their control groups are the suggested reference. With bamlanivimab, there was no emergence of resistance in the patients receiving 7000 mg, but resistance was reported in patients receiving 700 mg (8 cases: 7% vs 0% with placebo) [22]. Putative treatment-emergent bamlanivimab-resistant variants were detected in 7.1% of patients (7/98) in the 700 mg group, 9.8% of patients (10/102) in the 2800 mg group, 11.3% of patients (11/97) in the 7000 mg group, 1% of patients (1/102) in the bamlanivimab and etesevimab combination group, and in 4.8% of patients (7/145) in the placebo group. The bamlanivimab monotherapy groups had a higher frequency of patients in whom a variant was detected at more than 1 time point during the viral time course (4.1% for the 700 mg group, 5.9% for the 2800 mg group, and 7.2% for the 7000 mg group) than the placebo group or the bamlanivimab and etesevimab combination group (both 0%) [29]. Apart from registration trials, the largest case series to date evaluated the impact of mAbs on the nasopharyngeal (NP) viral load and virus quasi-species of mAb-treated patients using single-molecule real-time sequencing after bamlanivimab alone (4 patients), bamlanivimab/etesevimab (23 patients) and casirivimab/Imdevimab (5 patients) [32]. To date a single case of immune escape has been reported for the non-overlapping REGN-COV2 cocktail, and accordingly hamster models and clinical trials showed no emergence of variants [52]. Since mAb therapy by definition targets only a single epitope within the RBD, it is unsurprising that escape mutations observed after *in vitro* and *in vivo* selection by these mAbs were single amino acid substitutions localized almost exclusively to the RBD (Figure 2, bottom panel; Tables 1 and 2), as expected from *in vitro* studies with single mAb, but largely prevented by non-overlapping mAb cocktails [53].

In contrast to mAb therapeutics, immune escape under CCP has not been investigated in RCTs. Hence evidences exclusively stem from case series and case reports [54], and is further complicated by exposure to multiple CCP units from different donors, each one having a polyclonal response at differing titers and affinity. Unfortunately nAb titers were very rarely determined or reported, precluding correlations between emergence of resistance and subneutralizing CCP doses. Overall, it seems that escape variants from CCP selection have not been reported as commonly nor emerged as fast. E.g., none out of 8 recipients of HSCT or CART who were treated with CCP and tested SARS-CoV-2-positive for 2 months showed significant mutations compared to the original strain [55]. Review of the Spike protein changes associated with resistance after CCP therapy reveal that most of them had in-frame amino acid deletions in a flexible region that is partially solvent exposed and forms a β strand: plasticity may contribute to the structural permissibility of the identified deletions. The NTD is a flexible region that can be affected by immune escape via either insertions (causing additional glycosylation sites [11]) or recurrently deleted regions (RDR) Δ HV69–70 (RDR1), Δ LGYY141–144 and Δ D146 (RDR2), Δ I210 (RDR3) and Δ AL243–244 (RDR4) [56] : RDR1, RDR2 and RDR4 correspond to NTD loops N2, N3 and N5, whereas RDR3 falls between N4 and N5.

Deletions of amino acids from a protein structure generally results in greater structural changes than single amino acid changes, since these reduce the size of the protein and can trigger changes that propagate through the whole structure. Furthermore, the mechanism for the emergence of deletion variants appears to be very different from the single amino acid changes that are frequent from error-prone RNA replication and could involve deletions from RNA editing. Since CCP targets a large number of epitopes in the Spike protein while mAbs target a single epitope these molecular differences parallel what is expected from their respective selection pressures in the sense that escape from polyclonal preparations requires larger antigenic structural changes than escape from mAbs. In contrast to escape mutations selected for by mAb therapy, CCP selection yields point mutations throughout the Spike protein. This reflects the vast antigenic surface area covered by the polyclonal antibodies within CCP. Escape mutations would be theoretically selected for on the basis of the most potent antibodies present in a particular CCP unit, which may vary markedly from donor to donor, which could explain the generally divergent evolution of SARS-CoV-2 in the presence of CCP. However, residues 141-144 and 243-244 are the sites of mutations or deletions in several cases, indicating these sites may offer effective escape from CCP derived from many donors, possibly by triggering a large-scale conformational rearrangement, as discussed above. As RBD binding antibodies are often neutralizing via ACE2 receptor occlusion, it is interesting that only 23% of CCP case studies identified escape mutations within the RBD (Figure 2, top panel; Table 3). This suggests that antibody binding to other sites on the Spike protein may have additional mechanisms of neutralization (i.e., by preventing conformational change after ACE2 engagement), or that additional antibody mediated immune responses (e.g., ADCC) are equally important as direct neutralization to the antiviral response to SARS-CoV-2.

Nothing can be inferred about the fitness of an emerging mutant in the absence of selective pressure, but it is of interest that one variant with the E484K mutant that emerged after bamlanivimab therapy was able to infect multiple household contacts [27]. *In vitro*, several mutants showed similar infectivity to wild type strain but resistance to different CCP donors [36]. In one instance of immune escape associated with CCP, a variant with D796H mutation manifested modestly reduced sensitivity to neutralization by CCP that was associated with reduced infectivity, which was only partly compensated by Δ HV69-70 [36]. Even if immune escape in registration trials has been a rare phenomenon, it should be considered that in the real-world practice mAbs targeting the SARS-CoV-2 Spike protein are being reserved for use in high-risk (immunocompromised) patients. Considering the huge size of a pandemic, the likelihood of immune escape becomes relevant, raising the possibility that rare variants with enhanced fitness could drive next pandemic waves. Notably, several mutations have recurred in VOC and VOIs (e.g. E484K found in Beta and Gamma, E484Q found in Delta, or Δ LHR244-246 [41] found in VOI lambda), raising the possibility that such variants emerged during treatment of patients (iatrogenic variants), but such inference will likely remain very hard to prove. E406W mutation has never been reported in GISAID, and other E406 mutations remain exceedingly rare (worldwide 318 cases of E406Q, 41 cases of E406D, and 2 cases each from USA for E406G, E406A, E406K, and 1 case of E406V out of 4,410,787 sequences deposited in GISAID as of October 25, 2021). Similarly, Q493R has only been reported in 244 sequences and Q493K in 138 sequences (source: [Outbreak.info](https://outbreak.info)). Lack of fixation of those mutation facilitates the imputation that these require mAb selective pressure and/or effective infection control techniques in the care of those patients prevented spill over to the general population.

Within host variation (so-called “quasi-species swarm”) is a natural phenomenon which has been reported for SARS-CoV-2 in immunocompetent patients and ultimately facilitates persistence of infection. Among 33 patients having positive NPS PCR for an average of 18 days, Voloch *et al* observed a distinguishing pattern of mutations over the course of the infection mainly driven by

increasing A→U and decreasing G→A signatures, including Spike mutations (V362L, T531, H655Y, A688V, S691F, S884F, V1176F). G→A mutations are driven by RNA-editing enzyme activities typical of innate immunity [57]. Nevertheless, several covariates can facilitate immune escape.

Immunosuppression has been postulated to be an accelerator for viral evolution. Actually, Table 4 shows that very few case reports have detailed intraclonal (within-host) evolution in patients receiving immunosuppressive treatment, and, in the absence of nAb-based therapeutics, Spike mutations rarely occurred [55].

On the other hand, co-administered small chemical antivirals can be mutagenic *per se*. Remdesivir can adopt both amino and imino tautomeric conformations to base-pair with RNA bases [58]. Both amino-remdesivir:G and imino-remdesivir:C pairs could be quite mutagenic. Serial *in vitro* passages of SARS-CoV-2Eng12 in cell culture media supplemented with remdesivir selected for drug-resistant viral populations. Remdesivir triggers the selection of SARS-CoV-2 variant with a E802D mutation in the RdRp sufficient to confer decreased sensitivity to remdesivir without affecting viral fitness. The analysis of more than 200,000 sequences also revealed the occurrence of 22 mutations in Spike, including changes in amino acids E484 and N501 corresponding to mutations identified in Alpha and Beta [59]. It has been hence proposed that nAb-based therapeutics could amplify mutations induced by remdesivir [3]. In this regard, Table 4 shows that many of the mAb- or CCP-associated mutations emerged in individuals who were or had been treated with remdesivir (but neither mAbs nor CCP), consistent with the notion that antiviral therapy could potentiate the emergence of antibody-resistance mutations.

Conclusion

In summary, our survey of the available mutational data show that escape variants associated with mAb and CCP therapy manifest different type of mutations. For mAbs most mutations are single amino acid replacements in the RBD domain, while most variants eliciting in patients treated with CCP exhibited amino acid deletions. In fact, it is noteworthy that RBD mutations were relatively rare in CCP escape variants. Although the numbers are relatively small, which suggests caution in making generalizations, this dichotomy in geography of mAb and CCP mutations could reflect the fact that mAbs target a single epitope where the mAb-antigen interaction can be significantly altered by single amino acid changes while CCP targets many epitopes and has several mechanisms of action, such that evading polyclonal antibody immunity is likely to require much larger Spike protein structural changes. Despite the relatively small set of variants for which there is molecular data available, the large variation of molecular solutions that allow SARS-CoV-2 to escape antibody-mediated protection is striking and suggest the need for continued vigilance in genomic surveillance, especially in cases refractory to therapy.

We declare we don't have any conflict of interest related to this manuscript.

References

1. Van Egeren, D.; Novokhodko, A.; Stoddard, M.; Tran, U.; Zetter, B.; Rogers, M.; Pentelute, B. L.; Carlson, J. M.; Hixon, M. S.; Joseph-McCarthy, D.; Chakravarty, A., Risk of evolutionary escape from neutralizing antibodies targeting SARS-CoV-2 spike protein. **2020**, 2020.11.17.20233726.
2. Landis, J.; Moorad, R.; Pluta, L. J.; Caro-Vegas, C.; McNamara, R. P.; Eason, A. B.; Bailey, A.; Villamor, F. C. S.; Juarez, A.; Wong, J. P.; Yang, B.; Broussard, G. S.; Damania, B.; Dittmer, D.,

- 281 Intra-host evolution provides for continuous emergence of SARS-CoV-2 variants. **2021**,
282 2021.05.08.21256775.
- 283 3. Colson, P.; Devaux, C. A.; Lagier, J. C.; Gautret, P.; Raoult, D., A Possible Role of Remdesivir
284 and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 Variants.
285 *Journal of clinical medicine* **2021**, 10, (15).
- 286 4. Kabinger, F.; Stiller, C.; Schmitzová, J.; Dienemann, C.; Hillen, H. S.; Höbartner, C.; Cramer, P.,
287 Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. **2021**, 2021.05.11.443555.
- 288 5. Starr, T. N.; Greaney, A. J.; Hilton, S. K.; Ellis, D.; Crawford, K. H. D.; Dingens, A. S.; Navarro,
289 M. J.; Bowen, J. E.; Tortorici, M. A.; Walls, A. C.; King, N. P.; Veessler, D.; Bloom, J. D., Deep
290 Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding
291 and ACE2 Binding. *Cell* **2020**, 182, (5), 1295-1310.e20.
- 292 6. Greaney, A. J.; Starr, T. N.; Gilchuk, P.; Zost, S. J.; Binshtein, E.; Loes, A. N.; Hilton, S. K.;
293 Huddleston, J.; Eguia, R.; Crawford, K. H. D.; Dingens, A. S.; Nargi, R. S.; Sutton, R. E.;
294 Suryadevara, N.; Rothlauf, P. W.; Liu, Z.; Whelan, S. P. J.; Carnahan, R. H.; Crowe, J. E., Jr.;
295 Bloom, J. D., Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding
296 Domain that Escape Antibody Recognition. *Cell host & microbe* **2020**.
- 297 7. Javanmardi, K.; Chou, C.-W.; Terrace, C.; Annapareddy, A.; Kaoud, T. S.; Guo, Q.; Lutgens, J.;
298 Zorkic, H.; Horton, A. P.; Gardner, E. C.; Nguyen, G.; Boutz, D. R.; Goike, J.; Voss, W. N.; Kuo,
299 H.-C.; Dalby, K. N.; Gollihar, J. D.; Finkelstein, I. J., Rapid characterization of spike variants via
300 mammalian cell surface display. **2021**, 2021.03.30.437622.
- 301 8. Starr, T. N.; Greaney, A. J.; Addetia, A.; Hannon, W. W.; Choudhary, M. C.; Dingens, A. S.; Li, J.
302 Z.; Bloom, J. D., Prospective mapping of viral mutations that escape antibodies used to treat
303 COVID-19. *Science* **2021**, eabf9302.
- 304 9. Starr, T. N.; Greaney, A. J.; Dingens, A. S.; Bloom, J. D., Complete map of SARS-CoV-2 RBD
305 mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016.
306 *Cel Reports Medicine* **2021**, 2, (4), 100255.
- 307 10. Garrett, M. E.; Galloway, J.; Chu, H. Y.; Itell, H. L.; Stoddard, C. I.; Wolf, C. R.; Logue, J. K.;
308 McDonald, D.; Matsen, F. A.; Overbaugh, J., High resolution profiling of pathways of escape
309 for SARS-CoV-2 spike-binding antibodies. *bioRxiv* **2020**.
- 310 11. Andreano, E.; Piccini, G.; Licastro, D.; Casalino, L.; Johnson, N. V.; Paciello, I.; Dal Monego, S.;
311 Pantano, E.; Manganaro, N.; Manenti, A.; Manna, R.; Casa, E.; Hyseni, I.; Benincasa, L.;
312 Montomoli, E.; Amaro, R. E.; McLellan, J. S.; Rappuoli, R., SARS-CoV-2 escape in vitro from a
313 highly neutralizing COVID-19 convalescent plasma. *Proceedings of the National Academy of*
314 *Sciences of the United States of America* **2020**, 118, (36), e2103154118.
- 315 12. Wang, Z.; Schmidt, F.; Weisblum, Y.; Muecksch, F.; Barnes, C. O.; Finkin, S.; Schaefer-
316 Babajew, D.; Cipolla, M.; Gaebler, C.; Lieberman, J. A.; Yang, Z.; Abernathy, M. E.; Huey-
317 Tubman, K. E.; Hurley, A.; Turroja, M.; West, K. A.; Gordon, K.; Millard, K. G.; Ramos, V.; Silva,
318 J. D.; Xu, J.; Colbert, R. A.; Patel, R.; Dizon, J. P.; Unson-O'Brien, C.; Shimeliovich, I.;
319 Gazumyan, A.; Caskey, M.; Bjorkman, P. J.; Casellas, R.; Hatzioannou, T.; Bieniasz, P. D.;
320 Nussenzweig, M. C. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
321 <https://www.biorxiv.org/content/biorxiv/early/2021/01/19/2021.01.15.426911.full.pdf>
- 322 13. Casadevall, A.; Henderson, J.; Joyner, M.; Pirofski, L.-a., SARS-Cov2 variants and convalescent
323 plasma: reality, fallacies, and opportunities. *The Journal of clinical investigation* **2021**.
- 324 14. Valesano, A. L.; Rumfelt, K. E.; Dimcheff, D. E.; Blair, C. N.; Fitzsimmons, W. J.; Petrie, J. G.;
325 Martin, E. T.; Luring, A. S., Temporal dynamics of SARS-CoV-2 mutation accumulation within
326 and across infected hosts. **2021**, 2021.01.19.427330.
- 327 15. Page, M. J.; McKenzie, J. E.; Bossuyt, P. M.; Boutron, I.; Hoffmann, T. C.; Mulrow, C. D.;
328 Shamseer, L.; Tetzlaff, J. M.; Akl, E. A.; Brennan, S. E.; Chou, R.; Glanville, J.; Grimshaw, J. M.;
329 Hróbjartsson, A.; Lalu, M. M.; Li, T.; Loder, E. W.; Mayo-Wilson, E.; McDonald, S.;
330 McGuinness, L. A.; Stewart, L. A.; Thomas, J.; Tricco, A. C.; Welch, V. A.; Whiting, P.; Moher,

- 331 D., The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
332 **2021**, 372, n71.
- 333 16. Walls, A. C.; Park, Y. J.; Tortorici, M. A.; Wall, A.; McGuire, A. T.; Velesler, D., Structure,
334 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **2020**, 181, (2), 281-
335 292.e6.
- 336 17. Ju, B.; Zhang, Q.; Ge, J.; Wang, R.; Sun, J.; Ge, X.; Yu, J.; Shan, S.; Zhou, B.; Song, S.; Tang, X.;
337 Yu, J.; Lan, J.; Yuan, J.; Wang, H.; Zhao, J.; Zhang, S.; Wang, Y.; Shi, X.; Liu, L.; Zhao, J.; Wang,
338 X.; Zhang, Z.; Zhang, L., Human neutralizing antibodies elicited by SARS-CoV-2 infection.
339 *Nature* **2020**, 584, (7819), 115-119.
- 340 18. The PyMOL Molecular Graphics System, Version 2.4.1 Schrödinger, LLC.
- 341 19. Wang, P.; Nair, M. S.; Lihong, L.; Iketani, S.; Luo, Y.; Guo, Y.; Wang, M.; Yu, J.; Zhang, B.;
342 Kwong, P. D.; Graham, B. S.; Mascola, J. R.; Chang, J. Y.; Yin, M. T.; Sobieszczyk, M. E.;
343 Kyratsous, C. A.; Shapiro, L.; Sheng, Z.; Huang, Y.; Ho, D. D., Antibody resistance of SARS-CoV-
344 2 variants B.1.351 and B.1.1.7. *Nature* **2021**, 593, 130-135.
- 345 20. Choi, B.; Choudhary, M. C.; Regan, J.; Sparks, J. A.; Padera, R. F.; Qiu, X.; Solomon, I. H.; Kuo,
346 H.-H.; Boucau, J.; Bowman, K.; Adhikari, U. D.; Winkler, M. L.; Mueller, A. A.; Hsu, T. Y.-T.;
347 Desjardins, M.; Baden, L. R.; Chan, B. T.; Walker, B. D.; Lichterfeld, M.; Brigl, M.; Kwon, D. S.;
348 Kanjilal, S.; Richardson, E. T.; Jonsson, A. H.; Alter, G.; Barczak, A. K.; Hanage, W. P.; Yu, X. G.;
349 Gaiha, G. D.; Seaman, M. S.; Cernadas, M.; Li, J. Z., Persistence and Evolution of SARS-CoV-2
350 in an Immunocompromised Host. **2020**, 383, (23), 2291-2293.
- 351 21. Clark, S. A.; Clark, L. E.; Pan, J.; Coscia, A.; McKay, L. G. A.; Shankar, S.; Johnson, R. I.; Brusic,
352 V.; Choudhary, M. C.; Regan, J.; Li, J. Z.; Griffiths, A.; Abraham, J., SARS-CoV-2 evolution in an
353 immunocompromised host reveals shared neutralization escape mechanisms. *Cell* **2021**,
354 184, (10), 2605-2617.e18.
- 355 22. Choudhary, M. C.; Chew, K. W.; Deo, R.; Flynn, J. P.; Regan, J.; Crain, C. R.; Moser, C.; Hughes,
356 M.; Ritz, J.; Ribeiro, R. M.; Ke, R.; Dragavon, J. A.; Javan, A. C.; Nirula, A.; Klekotka, P.;
357 Greninger, A. L.; Fletcher, C. V.; Daar, E. S.; Wohl, D. A.; Eron, J. J.; Currier, J. S.; Parikh, U. M.;
358 Sieg, S. F.; Perelson, A. S.; Coombs, R. W.; Smith, D. M.; Li, J. Z., Emergence of SARS-CoV-2
359 Resistance with Monoclonal Antibody Therapy. *medRxiv* **2021**.
- 360 23. Truffot, A.; Andreani, J.; Le Marechal, M.; Caporossi, A.; Epaulard, O.; Poinard, P.; Sylvie, L.,
361 SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy.
362 *Emerging infectious diseases* **2021**, 27, (10).
- 363 24. Lohr, B.; Niemann, D.; Verheyen, J., Bamlanivimab treatment leads to rapid selection of
364 immune escape variant carrying E484K mutation in a B.1.1.7 infected and
365 immunosuppressed patient. *Clinical infectious diseases : an official publication of the*
366 *Infectious Diseases Society of America* **2021**.
- 367 25. Jensen, B.; Luebke, N.; Feldt, T.; Keitel, V.; Brandenburger, T.; Kindgen-Milles, D.; Lutterbeck,
368 M.; Freise, N. F.; Schoeler, D.; Haas, R.; Diltthey, A.; Adams, O.; Walker, A.; Timm, J.; Luedde,
369 T., Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients
370 treated with bamlanivimab in Germany. *The Lancet Regional Health – Europe* **2021**, 8.
- 371 26. Bronstein, Y.; Adler, A.; Katash, H.; Halutz, O.; Y, H.; Levytskyi, K., Evolution of spike
372 mutations following antibody treatment in two immunocompromised patients with
373 persistent COVID-19 infection. *Journal of medical virology* **2021**.
- 374 27. Sabin, A. P.; Richmond, C. S.; Kenny, P. A., Acquisition and onward transmission of a SARS-
375 CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient. **2021**,
376 2021.10.02.21264415.
- 377 28. Peiffer-Smadja, N.; Bridier-Nahmias, A.; Ferré, V. M.; Charpentier, C.; Garé, M.; Rioux, C.;
378 Allemand, A.; Lavallée, P.; Ghosn, J.; Kramer, L.; Descamps, D.; Yazdanpanah, Y.; Visseaux, B.,
379 Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk
380 Patients Infected with the Alpha Variant of SARS-CoV-2. *Viruses* **2021**, 13, (8).

- 381 29. Gottlieb, R. L.; Nirula, A.; Chen, P.; Boscia, J.; Heller, B.; Morris, J.; Huhn, G.; Cardona, J.;
382 Mocherla, B.; Stosor, V.; Shawa, I.; Kumar, P.; Adams, A. C.; Van Naarden, J.; Custer, K. L.;
383 Durante, M.; Oakley, G.; Schade, A. E.; Holzer, T. R.; Ebert, P. J.; Higgs, R. E.; Kallewaard, N. L.;
384 Sabo, J.; Patel, D. R.; Klekotka, P.; Shen, L.; Skovronsky, D. M., Effect of Bamlanivimab as
385 Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to
386 Moderate COVID-19: A Randomized Clinical Trial. *JAMA* **2021**, 325, (7), 632-644.
- 387 30. Focosi, D.; Novazzi, F.; Genoni, A.; Dentali, F.; Dalla Gasperina, D.; Baj, A.; Maggi, F., Daniele
388 Focosi, Federica Novazzi, Angelo Genoni, Francesco Dentali, Daniela Dalla gasperina,
389 Andreina Baj, Fabrizio Maggi. **2021**.
- 390 31. Guigon, A.; Faure, E.; Lemaire, C.; Chopin, M.; Tinez, C.; Assaf, A.; Lazrek, M.; Hober, D.;
391 Bocket, L.; Engelmann, I.; Kazali Alidjinou, E., Emergence of Q493R mutation in SARS-CoV-2
392 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance. *J*
393 *Infect* **2021**, S0163-4453, (21), 00435-7.
- 394 32. Vellas, C.; Del Bello, A.; Alexa, D.; Steinmeyer, Z.; Tribaudeau, L.; Ranger, N.; Jeanne, N.;
395 Martin-Blondel, G.; Delobel, P.; Kamar, N.; Izopet, J., Influence of neutralizing monoclonal
396 antibodies on the SARS-CoV-2 quasispecies in patients with COVID-19. *Clin Microb Infect*
397 **2021**.
- 398 33. Pommeret, F.; Colomba, J.; Bigenwald, C.; Laparra, A.; Bockel, S.; Bayle, A.; Michot, J. M.;
399 Hueso, T.; Albiges, L.; Tiberghien, P.; Marot, S.; Jary, A.; Lacombe, K.; Barlesi, F.; Griscelli, F.;
400 Colomba, E., Bamlanivimab+ etesevimab therapy induces SARS-CoV-2 immune escape
401 mutations and secondary clinical deterioration in COVID-19 patients with B-cell
402 malignancies. *Annals of Oncology* **2021**.
- 403 34. Avanzato, V. A.; Matson, M. J.; Seifert, S. N.; Pryce, R.; Williamson, B. N.; Anzick, S. L.;
404 Barbian, K.; Judson, S. D.; Fischer, E. R.; Martens, C.; Bowden, T. A.; de Wit, E.; Riedo, F. X.;
405 Munster, V. J., Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an
406 Asymptomatic Immunocompromised Individual with Cancer. *Cell* **2020**.
- 407 35. Hensley, M. K.; Bain, W. G.; Jacobs, J.; Nambulli, S.; Parikh, U.; Cillo, A.; Staines, B.; Heaps, A.;
408 Sobolewski, M. D.; Rennick, L. J.; Macatangay, B. J. C.; Klamar-Blain, C.; Kitsios, G. D.; Methé,
409 B.; Somasundaram, A.; Bruno, T.; Cardello, C.; Shan, F.; Workman, C.; Ray, P.; Ray, A.; Lee, J.;
410 Sethi, R.; Schwarzmann, W. E.; Ladinsky, M. S.; Bjorkman, P. J.; Vignali, D. A.; Duprex, W. P.;
411 Agha, M. E.; Mellors, J. W.; McCormick, K. D.; Morris, A.; Haidar, G., Intractable COVID-19
412 and Prolonged SARS-CoV-2 Replication in a CAR-T-cell Therapy Recipient: A Case Study.
413 *Clinical infectious diseases: an official publication of the Infectious Diseases Society of*
414 *America* **2021**.
- 415 36. Kemp, S. A.; Collier, D. A.; Datir, R.; Gayed, S.; Jahun, A.; Hosmillo, M.; Ferreira, I. A.; Rees-
416 Spear, C.; Mlcochova, P.; Lumb, I. U.; Roberts, D.; Chandra, A.; Temperton, N.; Sharrocks, K.;
417 Blane, E.; Briggs, J. A.; Smith, K. G.; Bradley, J. R.; Smith, C.; Goldstein, R.; Goodfellow, I. G.;
418 Smielewska, A.; Skittrall, J. P.; Gouliouris, T.; Gkrania-Klotsas, E.; Illingworth, C. J.; McCoy, L.
419 E.; Gupta, R. K., Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation. *Nature*
420 **2020**, 2020.12.05.20241927.
- 421 37. Truong, T. T.; Ryutov, A.; Pandey, U.; Yee, R.; Goldberg, L.; Bhojwani, D.; Aguayo-Hiraldo, P.;
422 Pinsky, B. A.; Pekosz, A.; Shen, L.; Boyd, S. D.; Wirz, O. F.; Roltgen, K.; Bootwalla, M.;
423 Maglinte, D. T.; Ostrow, D.; Ruble, D.; Han, J. H.; Biegel, J. A.; Li, M.; Huang, C.; Sahoo, M. K.;
424 Pannaraj, P. S.; O'Gorman, M.; Judkins, A. R.; Gai, X.; Dien Bard, J., Persistent SARS-CoV-2
425 infection and increasing viral variants in children and young adults with impaired humoral
426 immunity. *EBioMedicine* **2021**, 67, 103355.
- 427 38. Chen, L.; Zody, M. C.; Mediavilla, J. R.; Cunningham, M. H.; Composto, K.; Chow, K. F.;
428 Kordalewska, M.; Corvelo, A.; Oschwald, D. M.; Fennessey, S.; Zetkovic, M.; Dar, S.; Kramer,
429 Y.; Mathema, B.; Maniatis, T.; Perlin, D. S.; Kreiswirth, B. N., Emergence of multiple SARS-
430 CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent
431 plasma treatment. *mSphere* **2021**, 6, (4), e0048021.

39. Monrad, I.; Sahlertz, S. R.; Nielsen, S. S. F.; Pedersen, L.; Petersen, M. S.; Kobel, C. M.; Tarpgaard, I. H.; Storgaard, M.; Mortensen, K. L.; Schleimann, M. H.; Tolstrup, M.; Vibholm, L. K., Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral Evolution. *Open forum infectious diseases* **2021**, 8, (7), ofab295.
40. Baang, J. H.; Smith, C.; Mirabelli, C.; Valesano, A. L.; Manthei, D. M.; Bachman, M. A.; Wobus, C. E.; Adams, M.; Washer, L.; Martin, E. T.; Luring, A. S., Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. *J Infect Dis* **2021**, 223, (1), 23-27.
41. Nussenblatt, V.; Roder, A.; Das, S.; de Wit, E.; Youn, J.-H.; Banakis, S.; Muchegian, A.; Mederos, C.; Wang, W.; Chung, M.; Perez-Perez, L.; Palmore, T.; Brudno, J.; Kochenderfer, J.; Ghedin, E., Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion. **2021**, 2021.10.02.21264267.
42. Khatamzas, E.; Rehn, A.; Muenchhoff, M.; Hellmuth, J.; Gaitzsch, E.; Weiglein, T.; Georgi, E.; Scherer, C.; Stecher, S.; Weigert, O.; Giral, P.; Zange, S.; Keppler, O. T.; Stemmler, J.; von Bergwelt-Baildon, M.; Wölfel, R.; Antwerpen, M., Emergence of multiple SARS-CoV-2 mutations in an immunocompromised host. **2021**, 2021.01.10.20248871.
43. Sepulcri, C.; Dentone, C.; Mikulska, M.; Bruzzone, B.; Lai, A.; Fenoglio, D.; Bozzano, F.; Bergna, A.; Parodi, A.; Altosole, T.; Delfino, E.; Bartalucci, G.; Orsi, A.; Di Biagio, A.; Zehender, G.; Ballerini, F.; Bonora, S.; De Palma, R.; Silvestri, G.; De Maria, A.; Bassetti, M., The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient – a case study. *Open forum infectious diseases* **2021**, ofab217, 2021.01.23.21249554.
44. Mendes-Correa, M. C.; Ghilardi, F.; Salomao, M. C.; Villas-Boas, L. S.; Vincente de Paula, A.; Tozetto-Mendoza, T. R.; Freire, W.; Sales, F. C. d. S.; Romano, C. M.; Claro, I. M.; de Souza, L. M.; Ramos, J. F.; Paiao, H. G. d. O.; Szor, R. S., SARS-CoV-2 shedding, infectivity and evolution in an immunocompromised adult patient. **2021**, 2021.06.11.21257717.
45. Bazykin, G.; Stanevich, O.; Danilenko, D.; Fadeev, A.; Komissarova, K.; Ivanova, A.; Sergeeva, M.; Safina, K.; Nabieva, E.; Klink, G.; Garushyants, S.; Zabutova, J.; Kholodnaia, A.; Skorokhod, I.; Ryabchikova, V.; Komissarov, A.; Lioznov, D. Emergence of Y453F and Δ69-70HV mutations in a lymphoma patient with long-term COVID-19. <https://virological.org/t/emergence-of-y453f-and-69-70hv-mutations-in-a-lymphoma-patient-with-long-term-covid-19/580>
46. Borges, V.; Isidro, J.; Cunha, M.; Cochicho, D.; Martins, L.; Banha, L.; Figueiredo, M.; Rebelo, L.; Trindade, M.; Duarte, S.; Vieira, L.; Alves, M.; Costa, I.; Guiomar, R.; Santos, M.; Cortê-Real, R.; Dias, A.; Póvoas, D.; Cabo, J.; Figueiredo, C.; Manata, M.; Maltez, F.; da Silva, M.; Gomes, J., Long-term evolution of SARS-CoV-2 in an immunocompromised patient with non-Hodgkin lymphoma. *mSphere* **2021**, e0024421.
47. Karim, F.; Moosa, M. Y.; Gosnell, B.; Sandile, C.; Giandhari, J.; Pillay, S.; Tegally, H.; Wilkinson, E.; San, E. J.; Msomi, N.; Mlisana, K.; Khan, K.; Bernstein, M.; Manickchand Nithendra, N.; Singh, L.; Ramphal, U.; Hanekom, W.; Lessells, R. J.; Sigal, A.; de Oliveira, T., Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection. **2021**, 2021.06.03.21258228.
48. Kavanagh Williamson, M.; Hamilton, F.; Hutchings, S.; Pymont, H. M.; Hackett, M.; Arnold, D.; Maskell, N.; MacGowan, A. P.; Albur, m.; Jenkins, M.; Heys, I.; Knapper, F.; Elsayed, M.; Milligan, R.; Muir, P.; Vipond, B.; Matthews, D. A.; Moran, E.; Davidson, A. D. D., Chronic SARS-CoV-2 infection and viral evolution in a hypogammaglobulinaemic individual. **2021**, 2021.05.31.21257591.
49. Weigang, S.; Fuchs, J.; Zimmer, G.; Schnepf, D.; Kern, L.; Beer, J.; Luxenburger, H.; Ankerhold, J.; Falcone, V.; Kemming, J.; Hofmann, M.; Thimme, R.; Neumann-Haefelin, C.; Ulferts, S.; Grosse, R.; Hornuss, D.; Tanriver, Y.; Rieg, S.; Wagner, D.; Huzly, D.; Schwemmler, M.;

- 482 Panning, M.; Kochs, G., Within-host evolution of SARS-CoV-2 in an immunosuppressed
483 COVID-19 patient: a source of immune escape variants. **2021**, 2021.04.30.21256244.
- 484 50. Lee, C. Y.; Shah, M. K.; Hoyos, D.; Solovyov, A.; Douglas, M.; Taur, Y.; Maslak, P. G.; Babady,
485 N. E.; Greenbaum, B.; Kamboj, M.; Vardhana, S. A., Prolonged SARS-CoV-2 infection in
486 patients with lymphoid malignancies. **2021**, 2021.08.25.21262417.
- 487 51. Focosi, D.; Franchini, M.; Pirofski, L. A.; Maggi, F.; Casadevall, A., Is SARS-CoV-2 viral
488 clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of
489 neutralizing antibody-based therapeutics? *Rev Med Virol* **2021**.
- 490 52. Copin, R.; Baum, A.; Wloga, E.; Pascal, K. E.; Giordano, S.; Fulton, B. O.; Zhou, A.; Negron, N.;
491 Lanza, K.; Chan, N.; Coppola, A.; Chiu, J.; Ni, M.; Atwal, G. S.; Romero Hernandez, A.;
492 Saotome, K.; Zhou, Y.; Franklin, M. C.; Hooper, A. T.; McCarthy, S.; Hamon, S.; Hamilton, J. D.;
493 Staples, H. M.; Alfson, K.; Carrion, R.; Ali, S.; Norton, T.; Somersan-Karakaya, S.;
494 Sivapalasingam, S.; Herman, G. A.; Weinreich, D. M.; Lipsich, L.; Stahl, N.; Murphy, A. J.;
495 Yancopoulos, G. D.; Kyratsous, C. A., REGEN-COV protects against viral escape in preclinical
496 and human studies. *bioRxiv [Preprint]* **2021**, 2021.03.10.434834.
- 497 53. Baum, A.; Fulton, B. O.; Wloga, E.; Copin, R.; Pascal, K. E.; Russo, V.; Giordano, S.; Lanza, K.;
498 Negron, N.; Ni, M.; Wei, Y.; Atwal, G. S.; Murphy, A. J.; Stahl, N.; Yancopoulos, G. D.;
499 Kyratsous, C. A., Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational
500 escape seen with individual antibodies. **2020**, 369, (6506), 1014-1018.
- 501 54. Harvey, W. T.; Carabelli, A. M.; Jackson, B.; Gupta, R. K.; Thomson, E. C.; Harrison, E. M.;
502 Ludden, C.; Reeve, R.; Rambaut, A.; Peacock, S. J.; Robertson, D. L.; Consortium, C.-G. U.,
503 SARS-CoV-2 variants, spike mutations and immune escape. *Nature Reviews Microbiology*
504 **2021**, 19, (7), 409-424.
- 505 55. Aydillo, T.; Gonzalez-Reiche, A. S.; Aslam, S.; van de Guchte, A.; Khan, Z.; Obla, A.; Dutta, J.;
506 van Bakel, H.; Aberg, J.; García-Sastre, A.; Shah, G.; Hohl, T.; Papanicolaou, G.; Perales, M.-A.;
507 Sepkowitz, K.; Babady, N. E.; Kamboj, M., Shedding of Viable SARS-CoV-2 after
508 Immunosuppressive Therapy for Cancer. **2020**, 383, (26), 2586-2588.
- 509 56. McCarthy, K. R.; Rennick, L. J.; Nambulli, S.; Robinson-McCarthy, L. R.; Bain, W. G.; Haidar, G.;
510 Duprex, W. P., Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody
511 escape. *Science* **2021**, 371, (6534), 1139-1142.
- 512 57. Voloch, C. M.; da Silva Francisco Jr, R.; de Almeida, L. G. P.; Brustolini, O. J.; Cardoso, C. C.;
513 Gerber, A. L.; Guimarães, A. P. d. C.; Leitão, I. d. C.; Mariani, D.; Ota, V. A.; Lima, C. X.;
514 Teixeira, M. M.; Dias, A. C. F.; Galliez, R. M.; Faffe, D. S.; Pôrto, L. C.; Aguiar, R. S.; Castiñeira,
515 T. M. P. P.; Ferreira, O. C.; Tanuri, A.; de Vasconcelos, A. T. R., Intra-host evolution during
516 SARS-CoV-2 prolonged infection. *Virus Evolution* **2021**, 7, (2).
- 517 58. Singh, V.; Fedeles, B. I.; Essigmann, J. M., Role of tautomerism in RNA biochemistry. *RNA*
518 *(New York, N.Y.)* **2015**, 21, (1), 1-13.
- 519 59. Szemiel, A. M.; Merits, A.; Orton, R. J.; MacLean, O.; Pinto, R. M.; Wickenhagen, A.; Lieber,
520 G.; Turnbull, M. L.; Wang, S.; Mair, D.; da Silva Filipe, A.; Willett, B. J.; Wilson, S. J.; Patel, A.
521 H.; Thomson, E. C.; Palmarini, M.; Kohl, A.; Stewart, M. E., *In vitro* evolution of
522 Remdesivir resistance reveals genome plasticity of SARS-CoV-2. **2021**, 2021.02.01.429199.

523